Vivos Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VVOS | XAIR | ALBIO.PA | TLT.V | BVS | TLSI | |
|---|---|---|---|---|---|---|
| Market cap | 3.74M | 3.88M | 15.48M | 57.44M | 781.98M | 239.53M |
| P/E (TTM) | — | — | — | — | 14.1 | — |
| Forward P/E | -0.1 | -1.4 | 1.8 | -18.5 | 12.5 | -15.6 |
| Price/book | -0.3 | 0.9 | 0.4 | 8.0 | 3.3 | 36.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −95.47% | −93.83% | +56.67% | −10.00% | +48.31% | −21.80% |
| Today | +1.28% | +0.43% | +2.44% | +2.78% | +4.34% | +11.78% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All VVOS news ›Vivos Therapeutics (Nasdaq: VVOS) regains Nasdaq compliance after SOD deal
Posted by Michael Walen on Oct 21st, 2026 Vivos Therapeutics, Inc. (Nasdaq: VVOS) said Nasdaq's Listing Qualifications staff told it on October 20, 2026, that it now complies with Rule 5550(b)(1). The rule requires stockholders' equity of…
Vivos Therapeutics confirms Nasdaq compliance with $2.5M stockholders’ equity after SOD transaction
TradingView Vivos Therapeutics confirms Nasdaq compliance with $2.5M stockholders’ equity after SOD transaction Vivos Therapeutics confirmed compliance with Nasdaq's $2.5 million stockholders’ equity
SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic‑disease patients The partnership at a glance The ReBalU Protocol works in three steps: The…
Vivos Therapeutics reports Nasdaq compliance confirmation with continued listing shareholders’ equity standard
TradingView Vivos Therapeutics reports Nasdaq compliance confirmation with continued listing shareholders’ equity standard More news from Seeking Alpha
Vivos Therapeutics Acquires Stake in SOD Sciences and Half Interest in Pseudohypoxia Early-Warning Test
Vivos Therapeutics acquires equity in SOD Sciences and co-ownership of a chronic disease test, enhancing its market presence. Vivos announced the acquisition of an 11% stake in SOD Sciences and a 50% interest in a new chronic disease test.…
Vivos Therapeutics Finalizes Asset and Stock Purchase Agreement with SOD Sciences on October 16, 2026
Kalkine Media Did Stronger Steel Earnings Put Nucor (NYSE:NUE) in Focus? Did Stronger Aluminum Earnings Put Alcoa (NYSE:AA) in Focus? On October 19, 2026, Vivos Therapeutics, Inc. submitted a Form 8
Vivos Therapeutics agrees to $12M preferred-share swap
Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset Micron to Host Technology Webinar on Oct. 21 Knox and Palantir Partner to Further Accelerate Delivery of…
Vivos Therapeutics acquires 50% interest in SOD test
Polar Power Completes Phase 1 of Strategic Restructuring, Reducing Annualized Costs by More Than $1 Million Conversion is capped at 6,718,517 common shares until stockholders approve issuance above the Exchange Cap. The 12,000 preferred…
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
Polar Power Completes Phase 1 of Strategic Restructuring, Reducing Annualized Costs by More Than $1 Million The test interest carries rights to half its contribution margin, while planned distribution arrangements remain conditional.…
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
--Vivos Therapeutics, Inc., a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea and other health conditions related to…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net5
- tradingview.com4
- quiverquant.com2
- seekingalpha.com2
- kalkinemedia.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 16 articles, not a forecast.